Postapproval Comparative Safety Study of Tofacitinib and Biological Disease‐Modifying Antirheumatic Drugs: 5‐Year Results from a United States–Based Rheumatoid Arthritis Registry

Objective Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We compared 5‐year adverse event (AE) incidence rates (IRs) between patients initiating tofacitinib and those initiating new biological disease‐modifying antirheumatic drugs (bDMARDs) within the U...

Full description

Saved in:
Bibliographic Details
Published inACR open rheumatology Vol. 3; no. 3; pp. 173 - 184
Main Authors Kremer, Joel M., Bingham, Clifton O., Cappelli, Laura C., Greenberg, Jeffrey D., Madsen, Ann M., Geier, Jamie, Rivas, Jose L., Onofrei, Alina M., Barr, Christine J., Pappas, Dimitrios A., Litman, Heather J., Dandreo, Kimberly J., Shapiro, Andrea B., Connell, Carol A., Kavanaugh, Arthur
Format Journal Article
LanguageEnglish
Published United States John Wiley & Sons, Inc 01.03.2021
John Wiley and Sons Inc
Wiley
Subjects
Clinical trials
Comparative analysis
Data collection
Drug dosages
FDA approval
Original
Patients
Prescription drugs
Rheumatoid arthritis
United States > US
Online AccessGet full text

Cover

Abstract Objective Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We compared 5‐year adverse event (AE) incidence rates (IRs) between patients initiating tofacitinib and those initiating new biological disease‐modifying antirheumatic drugs (bDMARDs) within the United States (US) Corrona RA registry. Methods IRs (number of first events/100 patient‐years) of major adverse cardiovascular events (MACE), serious infection events (SIEs), herpes zoster (HZ), malignancies, and death were estimated among tofacitinib and bDMARD initiators, regardless of dose/schedule, between November 6, 2012 (US Food and Drug Administration tofacitinib approval), and July 31, 2018 (follow‐up through January 31, 2019). Propensity score (PS) methods were used to control for nonrandom prescribing practices. Hazard ratios (HRs) were calculated to compare rates using multivariable‐adjusted Cox regression. Different risk windows were used for acute (MACE, SIEs, HZ, and venous thromboembolic events [VTEs]) and long‐term (malignancy and death) events. VTEs were assessed descriptively. Results For MACE, SIEs, and HZ, 1999 (3152.1 patient‐years) and 8358 (12 869.4 years) tofacitinib and bDMARD initiators were included, respectively; for malignancy/death, 1999 (4505.6 patient‐years) and 6354 (16 670.8 patient‐years) initiators were included, respectively. AE rates were similar across cohorts, except for HZ, which was significantly higher with tofacitinib versus bDMARDs (PS‐trimmed adjusted HR 2.32; 95% confidence interval [CI] 1.43‐3.75). There were 45 (zero serious) and 88 (five serious) HZ events with tofacitinib and bDMARDs, respectively. Sensitivity analyses demonstrated similar results. VTE IRs (95% CI) were 0.29 (0.13‐0.54) and 0.33 (0.24‐0.45) for tofacitinib and bDMARDs, respectively. Conclusion In this registry analysis, both cohorts had similar MACE, SIE, malignancy, death, and VTE rates; HZ rates were higher for tofacitinib initaitors than for bDMARD initiators.
AbstractList ObjectiveTofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We compared 5‐year adverse event (AE) incidence rates (IRs) between patients initiating tofacitinib and those initiating new biological disease‐modifying antirheumatic drugs (bDMARDs) within the United States (US) Corrona RA registry.MethodsIRs (number of first events/100 patient‐years) of major adverse cardiovascular events (MACE), serious infection events (SIEs), herpes zoster (HZ), malignancies, and death were estimated among tofacitinib and bDMARD initiators, regardless of dose/schedule, between November 6, 2012 (US Food and Drug Administration tofacitinib approval), and July 31, 2018 (follow‐up through January 31, 2019). Propensity score (PS) methods were used to control for nonrandom prescribing practices. Hazard ratios (HRs) were calculated to compare rates using multivariable‐adjusted Cox regression. Different risk windows were used for acute (MACE, SIEs, HZ, and venous thromboembolic events [VTEs]) and long‐term (malignancy and death) events. VTEs were assessed descriptively.ResultsFor MACE, SIEs, and HZ, 1999 (3152.1 patient‐years) and 8358 (12 869.4 years) tofacitinib and bDMARD initiators were included, respectively; for malignancy/death, 1999 (4505.6 patient‐years) and 6354 (16 670.8 patient‐years) initiators were included, respectively. AE rates were similar across cohorts, except for HZ, which was significantly higher with tofacitinib versus bDMARDs (PS‐trimmed adjusted HR 2.32; 95% confidence interval [CI] 1.43‐3.75). There were 45 (zero serious) and 88 (five serious) HZ events with tofacitinib and bDMARDs, respectively. Sensitivity analyses demonstrated similar results. VTE IRs (95% CI) were 0.29 (0.13‐0.54) and 0.33 (0.24‐0.45) for tofacitinib and bDMARDs, respectively.ConclusionIn this registry analysis, both cohorts had similar MACE, SIE, malignancy, death, and VTE rates; HZ rates were higher for tofacitinib initaitors than for bDMARD initiators.
Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We compared 5-year adverse event (AE) incidence rates (IRs) between patients initiating tofacitinib and those initiating new biological disease-modifying antirheumatic drugs (bDMARDs) within the United States (US) Corrona RA registry.OBJECTIVETofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We compared 5-year adverse event (AE) incidence rates (IRs) between patients initiating tofacitinib and those initiating new biological disease-modifying antirheumatic drugs (bDMARDs) within the United States (US) Corrona RA registry.IRs (number of first events/100 patient-years) of major adverse cardiovascular events (MACE), serious infection events (SIEs), herpes zoster (HZ), malignancies, and death were estimated among tofacitinib and bDMARD initiators, regardless of dose/schedule, between November 6, 2012 (US Food and Drug Administration tofacitinib approval), and July 31, 2018 (follow-up through January 31, 2019). Propensity score (PS) methods were used to control for nonrandom prescribing practices. Hazard ratios (HRs) were calculated to compare rates using multivariable-adjusted Cox regression. Different risk windows were used for acute (MACE, SIEs, HZ, and venous thromboembolic events [VTEs]) and long-term (malignancy and death) events. VTEs were assessed descriptively.METHODSIRs (number of first events/100 patient-years) of major adverse cardiovascular events (MACE), serious infection events (SIEs), herpes zoster (HZ), malignancies, and death were estimated among tofacitinib and bDMARD initiators, regardless of dose/schedule, between November 6, 2012 (US Food and Drug Administration tofacitinib approval), and July 31, 2018 (follow-up through January 31, 2019). Propensity score (PS) methods were used to control for nonrandom prescribing practices. Hazard ratios (HRs) were calculated to compare rates using multivariable-adjusted Cox regression. Different risk windows were used for acute (MACE, SIEs, HZ, and venous thromboembolic events [VTEs]) and long-term (malignancy and death) events. VTEs were assessed descriptively.For MACE, SIEs, and HZ, 1999 (3152.1 patient-years) and 8358 (12 869.4 years) tofacitinib and bDMARD initiators were included, respectively; for malignancy/death, 1999 (4505.6 patient-years) and 6354 (16 670.8 patient-years) initiators were included, respectively. AE rates were similar across cohorts, except for HZ, which was significantly higher with tofacitinib versus bDMARDs (PS-trimmed adjusted HR 2.32; 95% confidence interval [CI] 1.43-3.75). There were 45 (zero serious) and 88 (five serious) HZ events with tofacitinib and bDMARDs, respectively. Sensitivity analyses demonstrated similar results. VTE IRs (95% CI) were 0.29 (0.13-0.54) and 0.33 (0.24-0.45) for tofacitinib and bDMARDs, respectively.RESULTSFor MACE, SIEs, and HZ, 1999 (3152.1 patient-years) and 8358 (12 869.4 years) tofacitinib and bDMARD initiators were included, respectively; for malignancy/death, 1999 (4505.6 patient-years) and 6354 (16 670.8 patient-years) initiators were included, respectively. AE rates were similar across cohorts, except for HZ, which was significantly higher with tofacitinib versus bDMARDs (PS-trimmed adjusted HR 2.32; 95% confidence interval [CI] 1.43-3.75). There were 45 (zero serious) and 88 (five serious) HZ events with tofacitinib and bDMARDs, respectively. Sensitivity analyses demonstrated similar results. VTE IRs (95% CI) were 0.29 (0.13-0.54) and 0.33 (0.24-0.45) for tofacitinib and bDMARDs, respectively.In this registry analysis, both cohorts had similar MACE, SIE, malignancy, death, and VTE rates; HZ rates were higher for tofacitinib initaitors than for bDMARD initiators.CONCLUSIONIn this registry analysis, both cohorts had similar MACE, SIE, malignancy, death, and VTE rates; HZ rates were higher for tofacitinib initaitors than for bDMARD initiators.
Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We compared 5-year adverse event (AE) incidence rates (IRs) between patients initiating tofacitinib and those initiating new biological disease-modifying antirheumatic drugs (bDMARDs) within the United States (US) Corrona RA registry. IRs (number of first events/100 patient-years) of major adverse cardiovascular events (MACE), serious infection events (SIEs), herpes zoster (HZ), malignancies, and death were estimated among tofacitinib and bDMARD initiators, regardless of dose/schedule, between November 6, 2012 (US Food and Drug Administration tofacitinib approval), and July 31, 2018 (follow-up through January 31, 2019). Propensity score (PS) methods were used to control for nonrandom prescribing practices. Hazard ratios (HRs) were calculated to compare rates using multivariable-adjusted Cox regression. Different risk windows were used for acute (MACE, SIEs, HZ, and venous thromboembolic events [VTEs]) and long-term (malignancy and death) events. VTEs were assessed descriptively. For MACE, SIEs, and HZ, 1999 (3152.1 patient-years) and 8358 (12 869.4 years) tofacitinib and bDMARD initiators were included, respectively; for malignancy/death, 1999 (4505.6 patient-years) and 6354 (16 670.8 patient-years) initiators were included, respectively. AE rates were similar across cohorts, except for HZ, which was significantly higher with tofacitinib versus bDMARDs (PS-trimmed adjusted HR 2.32; 95% confidence interval [CI] 1.43-3.75). There were 45 (zero serious) and 88 (five serious) HZ events with tofacitinib and bDMARDs, respectively. Sensitivity analyses demonstrated similar results. VTE IRs (95% CI) were 0.29 (0.13-0.54) and 0.33 (0.24-0.45) for tofacitinib and bDMARDs, respectively. In this registry analysis, both cohorts had similar MACE, SIE, malignancy, death, and VTE rates; HZ rates were higher for tofacitinib initaitors than for bDMARD initiators.
Objective Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We compared 5‐year adverse event (AE) incidence rates (IRs) between patients initiating tofacitinib and those initiating new biological disease‐modifying antirheumatic drugs (bDMARDs) within the United States (US) Corrona RA registry. Methods IRs (number of first events/100 patient‐years) of major adverse cardiovascular events (MACE), serious infection events (SIEs), herpes zoster (HZ), malignancies, and death were estimated among tofacitinib and bDMARD initiators, regardless of dose/schedule, between November 6, 2012 (US Food and Drug Administration tofacitinib approval), and July 31, 2018 (follow‐up through January 31, 2019). Propensity score (PS) methods were used to control for nonrandom prescribing practices. Hazard ratios (HRs) were calculated to compare rates using multivariable‐adjusted Cox regression. Different risk windows were used for acute (MACE, SIEs, HZ, and venous thromboembolic events [VTEs]) and long‐term (malignancy and death) events. VTEs were assessed descriptively. Results For MACE, SIEs, and HZ, 1999 (3152.1 patient‐years) and 8358 (12 869.4 years) tofacitinib and bDMARD initiators were included, respectively; for malignancy/death, 1999 (4505.6 patient‐years) and 6354 (16 670.8 patient‐years) initiators were included, respectively. AE rates were similar across cohorts, except for HZ, which was significantly higher with tofacitinib versus bDMARDs (PS‐trimmed adjusted HR 2.32; 95% confidence interval [CI] 1.43‐3.75). There were 45 (zero serious) and 88 (five serious) HZ events with tofacitinib and bDMARDs, respectively. Sensitivity analyses demonstrated similar results. VTE IRs (95% CI) were 0.29 (0.13‐0.54) and 0.33 (0.24‐0.45) for tofacitinib and bDMARDs, respectively. Conclusion In this registry analysis, both cohorts had similar MACE, SIE, malignancy, death, and VTE rates; HZ rates were higher for tofacitinib initaitors than for bDMARD initiators.
Objective Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We compared 5‐year adverse event (AE) incidence rates (IRs) between patients initiating tofacitinib and those initiating new biological disease‐modifying antirheumatic drugs (bDMARDs) within the United States (US) Corrona RA registry. Methods IRs (number of first events/100 patient‐years) of major adverse cardiovascular events (MACE), serious infection events (SIEs), herpes zoster (HZ), malignancies, and death were estimated among tofacitinib and bDMARD initiators, regardless of dose/schedule, between November 6, 2012 (US Food and Drug Administration tofacitinib approval), and July 31, 2018 (follow‐up through January 31, 2019). Propensity score (PS) methods were used to control for nonrandom prescribing practices. Hazard ratios (HRs) were calculated to compare rates using multivariable‐adjusted Cox regression. Different risk windows were used for acute (MACE, SIEs, HZ, and venous thromboembolic events [VTEs]) and long‐term (malignancy and death) events. VTEs were assessed descriptively. Results For MACE, SIEs, and HZ, 1999 (3152.1 patient‐years) and 8358 (12 869.4 years) tofacitinib and bDMARD initiators were included, respectively; for malignancy/death, 1999 (4505.6 patient‐years) and 6354 (16 670.8 patient‐years) initiators were included, respectively. AE rates were similar across cohorts, except for HZ, which was significantly higher with tofacitinib versus bDMARDs (PS‐trimmed adjusted HR 2.32; 95% confidence interval [CI] 1.43‐3.75). There were 45 (zero serious) and 88 (five serious) HZ events with tofacitinib and bDMARDs, respectively. Sensitivity analyses demonstrated similar results. VTE IRs (95% CI) were 0.29 (0.13‐0.54) and 0.33 (0.24‐0.45) for tofacitinib and bDMARDs, respectively. Conclusion In this registry analysis, both cohorts had similar MACE, SIE, malignancy, death, and VTE rates; HZ rates were higher for tofacitinib initaitors than for bDMARD initiators.
Author Madsen, Ann M.
Shapiro, Andrea B.
Barr, Christine J.
Dandreo, Kimberly J.
Litman, Heather J.
Cappelli, Laura C.
Kavanaugh, Arthur
Pappas, Dimitrios A.
Greenberg, Jeffrey D.
Bingham, Clifton O.
Geier, Jamie
Rivas, Jose L.
Kremer, Joel M.
Onofrei, Alina M.
Connell, Carol A.
AuthorAffiliation 8 Pfizer Peapack New Jersey
4 Pfizer New York New York USA
6 Corrona Waltham Massachusetts
3 Corrona, Waltham, Massachusetts, and New York University School of Medicine
7 Corrona, Waltham, Massachusetts, and Columbia University New York New York
9 Pfizer Groton Connecticut
10 University of California San Diego School of Medicine La Jolla
1 Albany Medical College Center for Rheumatology Albany New York
5 Pfizer SLU Madrid Spain
2 Johns Hopkins University Baltimore Maryland
AuthorAffiliation_xml – name: 6 Corrona Waltham Massachusetts
– name: 7 Corrona, Waltham, Massachusetts, and Columbia University New York New York
– name: 3 Corrona, Waltham, Massachusetts, and New York University School of Medicine
– name: 1 Albany Medical College Center for Rheumatology Albany New York
– name: 2 Johns Hopkins University Baltimore Maryland
– name: 9 Pfizer Groton Connecticut
– name: 5 Pfizer SLU Madrid Spain
– name: 4 Pfizer New York New York USA
– name: 8 Pfizer Peapack New Jersey
– name: 10 University of California San Diego School of Medicine La Jolla
Author_xml – sequence: 1
  givenname: Joel M.
  orcidid: 0000-0001-6674-9901
  surname: Kremer
  fullname: Kremer, Joel M.
  email: jkremer@joint-docs.com
  organization: Center for Rheumatology
– sequence: 2
  givenname: Clifton O.
  orcidid: 0000-0002-4752-5029
  surname: Bingham
  fullname: Bingham, Clifton O.
  organization: Johns Hopkins University
– sequence: 3
  givenname: Laura C.
  orcidid: 0000-0003-2795-7059
  surname: Cappelli
  fullname: Cappelli, Laura C.
  organization: Johns Hopkins University
– sequence: 4
  givenname: Jeffrey D.
  surname: Greenberg
  fullname: Greenberg, Jeffrey D.
  organization: Corrona, Waltham, Massachusetts, and New York University School of Medicine
– sequence: 5
  givenname: Ann M.
  surname: Madsen
  fullname: Madsen, Ann M.
  organization: Pfizer
– sequence: 6
  givenname: Jamie
  surname: Geier
  fullname: Geier, Jamie
  organization: Pfizer
– sequence: 7
  givenname: Jose L.
  surname: Rivas
  fullname: Rivas, Jose L.
  organization: Pfizer SLU
– sequence: 8
  givenname: Alina M.
  surname: Onofrei
  fullname: Onofrei, Alina M.
  organization: Corrona
– sequence: 9
  givenname: Christine J.
  surname: Barr
  fullname: Barr, Christine J.
  organization: Corrona
– sequence: 10
  givenname: Dimitrios A.
  orcidid: 0000-0001-8338-027X
  surname: Pappas
  fullname: Pappas, Dimitrios A.
  organization: Corrona, Waltham, Massachusetts, and Columbia University
– sequence: 11
  givenname: Heather J.
  surname: Litman
  fullname: Litman, Heather J.
  organization: Corrona
– sequence: 12
  givenname: Kimberly J.
  surname: Dandreo
  fullname: Dandreo, Kimberly J.
  organization: Corrona
– sequence: 13
  givenname: Andrea B.
  surname: Shapiro
  fullname: Shapiro, Andrea B.
  organization: Pfizer
– sequence: 14
  givenname: Carol A.
  surname: Connell
  fullname: Connell, Carol A.
  organization: Pfizer
– sequence: 15
  givenname: Arthur
  surname: Kavanaugh
  fullname: Kavanaugh, Arthur
  organization: San Diego School of Medicine
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33570260$$D View this record in MEDLINE/PubMed
BookMark eNp9kstu1DAYRiNUREvphgdAltggpCm2E1_CotJ0yqVSEWjaLlhZfxIn4yoTD7YzKLs-AhIvw_P0SfA0pWor1JUt-3zHF33Pk63OdjpJXhK8TzCm76B0dJ8QmtInyQ5lQk6YyNjWnfl2suf9BY4wYVjw7FmynaZMYMrxTvLnm_UBVitn19CimV2uwEEwa41OodZhQKehrwZka3RmayhNMJ0pEHQVOjS2tY0pY-zIeA1eX13--mIrUw-ma9C0C8YtdL-MthIdub7x7xGLyHcNDs2179vgUe3sEgE670zQVTwLgvZXl78Po61C8zFuTYWmLixcPNzHZGN8cMOL5GkNrdd7N-Nucv7xw9ns8-Tk66fj2fRkUnIs6QSA8zzPsjiImqaQ5lDUspK4YmWRapZhAaLGXHBgm1XQdVHglJIcl1hnPN1NjkdvZeFCrZxZghuUBaOuF6xrFLj4xFYrTvK6JLyQIqNZBVmOZVplhchLyknKRXQdjK5VXyx1VeouOGjvSe_vdGahGrtWIudcyjQK3twInP3Rax_U0vhSty102vZe0UxKxjjON-jrB-iF7V0Xv0pRiTmhkrP8UYphIkhG5IZ6dffetxf-V6MIvB2B0lnvna5vEYLVpqZqU1N1XdMI4wdwrFVsid282bT_j5Ax8tO0enhErqazOR0zfwFbd_22
CitedBy_id crossref_primary_10_1080_1744666X_2023_2247158
crossref_primary_10_1007_s40744_021_00399_5
crossref_primary_10_21518_ms2023_206
crossref_primary_10_1002_acr2_11479
crossref_primary_10_1080_14656566_2023_2200931
crossref_primary_10_33590_emjallergyimmunol_10114613
crossref_primary_10_1038_s41598_023_33718_7
crossref_primary_10_1136_rmdopen_2023_003392
crossref_primary_10_1007_s10238_024_01325_z
crossref_primary_10_1080_14740338_2024_2348575
crossref_primary_10_5582_ddt_2022_01028
crossref_primary_10_1007_s40744_024_00734_6
crossref_primary_10_1136_annrheumdis_2021_221915
crossref_primary_10_1016_j_tips_2022_02_008
crossref_primary_10_1056_NEJMoa2109927
crossref_primary_10_1177_1759720X251321917
crossref_primary_10_1038_s41598_023_44841_w
crossref_primary_10_1007_s11926_023_01122_9
crossref_primary_10_1136_rmdopen_2022_002614
crossref_primary_10_1007_s10067_021_05911_4
crossref_primary_10_1080_1744666X_2022_2064275
crossref_primary_10_1111_1756_185X_15070
crossref_primary_10_1093_rheumatology_kead198
crossref_primary_10_3904_kjim_2022_369
crossref_primary_10_3390_jcm13103000
crossref_primary_10_1177_20406223231178273
crossref_primary_10_1136_rmdopen_2022_002409
crossref_primary_10_1016_j_rpth_2024_102667
crossref_primary_10_1007_s40744_024_00693_y
crossref_primary_10_3899_jrheum_2023_0145
crossref_primary_10_1007_s40744_023_00621_6
crossref_primary_10_1080_25785826_2023_2172808
crossref_primary_10_1007_s10067_022_06471_x
crossref_primary_10_1002_art_42250
crossref_primary_10_1007_s10067_023_06836_w
crossref_primary_10_1016_j_mpmed_2021_12_007
crossref_primary_10_1038_s41584_022_00767_7
crossref_primary_10_1007_s40264_023_01333_0
crossref_primary_10_1016_j_reuma_2023_07_001
crossref_primary_10_1016_j_jaci_2021_08_004
crossref_primary_10_3390_life13122244
crossref_primary_10_17816_RCF204421_434
crossref_primary_10_3390_jcm12134527
crossref_primary_10_3904_kjm_2022_97_2_93
crossref_primary_10_1159_000531701
crossref_primary_10_3389_fimmu_2023_1267749
crossref_primary_10_1093_mr_roaf006
crossref_primary_10_1111_cts_70084
crossref_primary_10_1055_a_1334_7609
crossref_primary_10_3390_ph15010048
crossref_primary_10_1007_s00393_021_01125_w
crossref_primary_10_1186_s13075_023_03111_w
crossref_primary_10_3390_jcm12206690
crossref_primary_10_1089_derm_2023_0058
crossref_primary_10_7759_cureus_32240
crossref_primary_10_1007_s00393_022_01237_x
crossref_primary_10_1136_rmdopen_2023_003630
crossref_primary_10_3390_jcm13061821
crossref_primary_10_1093_rheumatology_kead163
crossref_primary_10_3389_fdsfr_2022_881556
crossref_primary_10_1002_acr_24966
crossref_primary_10_1016_j_phrs_2022_106359
crossref_primary_10_1038_s41584_023_01062_9
crossref_primary_10_47360_1995_4484_2023_435_449
crossref_primary_10_1136_ard_2023_223850
crossref_primary_10_3389_fphar_2023_1165711
crossref_primary_10_1136_rmdopen_2023_003648
crossref_primary_10_1136_rmdopen_2023_003489
crossref_primary_10_1136_ard_2022_223636
crossref_primary_10_1136_ard_2022_223357
crossref_primary_10_1136_ard_2022_223356
crossref_primary_10_1136_bmj_2022_070856
crossref_primary_10_3390_cancers15082197
crossref_primary_10_1007_s40744_023_00576_8
crossref_primary_10_3390_jcm13237185
crossref_primary_10_3389_fimmu_2023_1225160
crossref_primary_10_1016_j_ard_2025_01_024
crossref_primary_10_1080_1744666X_2022_2039630
crossref_primary_10_1016_j_reumae_2023_07_004
crossref_primary_10_1007_s00296_022_05270_6
crossref_primary_10_1080_14740338_2022_2020247
crossref_primary_10_3389_fcvm_2022_1012661
crossref_primary_10_1007_s10067_022_06415_5
crossref_primary_10_1007_s10067_022_06205_z
crossref_primary_10_1016_j_semarthrit_2022_152120
crossref_primary_10_1080_14740338_2022_2100343
crossref_primary_10_1080_1744666X_2022_2039122
crossref_primary_10_1055_a_2246_6536
crossref_primary_10_1136_rmdopen_2023_003029
crossref_primary_10_1136_ard_2022_223050
crossref_primary_10_3389_fimmu_2022_881705
crossref_primary_10_1136_ard_2022_222405
crossref_primary_10_51987_revhospitalbaires_v42i3_206
crossref_primary_10_1136_ard_2023_224049
crossref_primary_10_1007_s00393_023_01316_7
crossref_primary_10_1055_a_2347_9759
crossref_primary_10_4103_injr_injr_30_23
crossref_primary_10_1016_j_abd_2022_05_002
crossref_primary_10_1016_j_gastrohep_2024_502314
Cites_doi 10.1016/S0140-6736(17)31618-5
10.3899/jrheum.130683
10.1093/rheumatology/kel253
10.1002/art.40187
10.1002/art.34530
10.1002/art.37816
10.1186/s13075-015-0728-9
10.1056/NEJMoa1310476
10.1136/rmdopen-2017-000498
10.1002/art.33383
10.1186/s13075-016-0932-2
10.1056/NEJMoa1109071
10.1136/annrheumdis-2011-201244
10.1001/jamainternmed.2017.4332
10.1016/S0140-6736(16)30173-8
10.1002/acr.20494
10.1186/ar2904
10.1002/art.24567
10.1056/NEJMoa1112072
10.3109/14397595.2014.995875
10.1002/art.40803
10.1002/art.33419
10.1186/s13075-017-1496-5
10.1136/annrheumdis-2016-209131
10.1002/art.10524
10.7326/0003-4819-159-4-201308200-00006
10.1016/j.semarthrit.2016.05.014
10.1136/annrheumdis-2016-210457
10.1007/s40744-018-0097-3
10.1186/s13075-019-1866-2
10.1016/S2665-9913(19)30137-7
10.1136/annrheumdis-2011-200726
ContentType Journal Article
Copyright 2021 The Authors. published by Wiley Periodicals LLC on behalf of American College of Rheumatology.
2021 The Authors. ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.
2021. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2021 The Authors. published by Wiley Periodicals LLC on behalf of American College of Rheumatology.
– notice: 2021 The Authors. ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.
– notice: 2021. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 24P
AAYXX
CITATION
NPM
3V.
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1002/acr2.11232
DatabaseName Wiley Online Library Open Access
CrossRef
PubMed
ProQuest Central (Corporate)
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database
MEDLINE - Academic
Publicly Available Content Database
PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: 7X7
  name: Health & Medical Collection
  url: https://search.proquest.com/healthcomplete
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate TOFACITINIB VERSUS BDMARDS IN THE CORRONA REGISTRY
EISSN 2578-5745
EndPage 184
ExternalDocumentID oai_doaj_org_article_619fc16b87424da49083d4b79c261367
PMC7966883
33570260
10_1002_acr2_11232
ACR211232
Genre article
Journal Article
GeographicLocations United States--US
GeographicLocations_xml – name: United States--US
GrantInformation_xml – fundername: Pfizer Inc
– fundername: Corrona LLC
GroupedDBID 0R~
1OC
24P
53G
7X7
8FI
8FJ
AAHHS
ABUWG
ACCFJ
ACCMX
ACXQS
ADBBV
ADKYN
ADPDF
ADZMN
ADZOD
AEEZP
AEQDE
AFKRA
AIWBW
AJBDE
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AVUZU
BCNDV
BENPR
CCPQU
EBS
EJD
EMOBN
FYUFA
GROUPED_DOAJ
HMCUK
HYE
IAO
IHR
INH
ITC
M~E
OK1
OVD
OVEED
PIMPY
PQQKQ
RPM
TEORI
UKHRP
WIN
AAYXX
CITATION
PHGZM
PHGZT
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
NPM
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c6082-aa669944a667f23a39abf8d80d5cb3e5407a7f0676a5d80daefbb032190c0e463
IEDL.DBID 24P
ISSN 2578-5745
IngestDate Wed Aug 27 01:26:26 EDT 2025
Thu Aug 21 18:10:39 EDT 2025
Thu Jul 10 18:53:41 EDT 2025
Fri Jul 25 07:21:38 EDT 2025
Fri Jul 25 02:43:35 EDT 2025
Mon Jul 21 06:01:49 EDT 2025
Thu Apr 24 23:03:53 EDT 2025
Tue Jul 01 04:15:43 EDT 2025
Wed Jan 22 16:29:59 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Language English
License Attribution-NonCommercial-NoDerivs
2021 The Authors. ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.
This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c6082-aa669944a667f23a39abf8d80d5cb3e5407a7f0676a5d80daefbb032190c0e463
Notes Dimitrios A. Pappas, MD: Corrona, Waltham, Massachusetts, and Columbia University, New York, New York
Supported by Pfizer. The registry is sponsored by Corrona, LLC. Corrona has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol‐Myers Squibb, Celgene, Crescendo, Eli Lilly and Company, Genentech, Gilead, Glaxo Smith Kline, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc, Regeneron, Roche, Sun, and UCB. Medical writing support, under the guidance of the authors, was provided by Jennifer Stewart, PhD, MBA, and Anthony G. McCluskey, PhD, CMC Connect, McCann Health Medical Communications, and was funded by Pfizer in accordance with Good Publication Practice guidelines (Ann Intern Med 2015;163:461‐4). Corrona owns the Corrona Rheumatoid Arthritis registry. Pfizer paid a subscription fee to Corrona for access to the Corrona Rheumatoid Arthritis registry. Michelle Karpman at Corrona, LLC, provided medical writing support in accordance with Good Publication Practice guidelines (Ann Intern Med 2015;163:461‐4).
Joel M. Kremer has received research grants from AbbVie, Bristol‐Myers Squibb, Eli Lilly and Company, Genentech, Novartis, and Pfizer (more than $10 000 in total), and has received consulting fees or other remuneration from AbbVie, Amgen, Bristol‐Myers Squibb, Eli Lilly and Company, Genentech, Pfizer, and Regeneron/Sanofi (less than $10 000). Clifton O. Bingham III has received research grants from Bristol‐Myers Squibb (less than $10 000) and has received consulting fees or other remuneration from AbbVie, Bristol‐Myers Squibb, Eli Lilly and Company, Genentech/Roche, Gilead, Janssen, Pfizer, and Regeneron/Sanofi (less than $10 000 each). Laura C. Cappelli has received research grants from Bristol‐Myers Squibb and has received consulting fees or other remuneration from Regeneron/Sanofi Genzyme (less than $10 000). Jeffrey D. Greenberg is an employee and shareholder of Corrona. Ann M. Madsen is an employee and shareholder of Pfizer. Jamie Geier is an employee and shareholder of Pfizer. Jose L. Rivas is an employee and shareholder of Pfizer. Alina M. Onofrei is an employee of Corrona. Christine J. Barr is an employee and shareholder of Corrona. Dimitrios A. Pappas is an employee and shareholder of Corrona and has received consulting fees or other remuneration from Novartis, Roche, and Regeneron (less than $10 000). Heather J. Litman is an employee and shareholder of Corrona. Kimberly J. Dandreo is an employee of Corrona. Andrea B. Shapiro is an employee and shareholder of Pfizer. Carol A. Connell is an employee and shareholder of Pfizer. Arthur Kavanaugh has received research grants from Pfizer (less than $10 000). No other disclosures relevant to this article were reported.
Carol A. Connell, RN, PhD: Pfizer, Groton, Connecticut
The views and opinions expressed within this manuscript are those of all authors and do not necessarily represent those of the sponsor.
1
Alina M. Onofrei, MSc, Christine J. Barr, BSN, MPH, Heather J. Litman, PhD, Kimberly J. Dandreo, MSc: Corrona, Waltham, Massachusetts
2
3
Jeffrey D. Greenberg, MD: Corrona, Waltham, Massachusetts, and New York University School of Medicine
4
5
Jose L. Rivas, MD: Pfizer SLU, Madrid, Spain
6
Joel M. Kremer, MD: Albany Medical College, Center for Rheumatology, Albany, New York
7
8
Arthur Kavanaugh, MD: University of California, San Diego School of Medicine, La Jolla.
9
Clifton O. Bingham III, MD, Laura C. Cappelli, MD: Johns Hopkins University, Baltimore, Maryland
Ann M. Madsen, PhD, Jamie Geier, PhD: Pfizer, New York, New York, USA
Andrea B. Shapiro, MD, MS: Pfizer, Peapack, New Jersey
10
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0001-8338-027X
0000-0003-2795-7059
0000-0002-4752-5029
0000-0001-6674-9901
OpenAccessLink https://onlinelibrary.wiley.com/doi/abs/10.1002%2Facr2.11232
PMID 33570260
PQID 2501714189
PQPubID 4570193
PageCount 12
ParticipantIDs doaj_primary_oai_doaj_org_article_619fc16b87424da49083d4b79c261367
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7966883
proquest_miscellaneous_2488556093
proquest_journals_2806128659
proquest_journals_2501714189
pubmed_primary_33570260
crossref_primary_10_1002_acr2_11232
crossref_citationtrail_10_1002_acr2_11232
wiley_primary_10_1002_acr2_11232_ACR211232
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate March 2021
PublicationDateYYYYMMDD 2021-03-01
PublicationDate_xml – month: 03
  year: 2021
  text: March 2021
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Atlanta
– name: Hoboken
PublicationTitle ACR open rheumatology
PublicationTitleAlternate ACR Open Rheumatol
PublicationYear 2021
Publisher John Wiley & Sons, Inc
John Wiley and Sons Inc
Wiley
Publisher_xml – name: John Wiley & Sons, Inc
– name: John Wiley and Sons Inc
– name: Wiley
References 2010; 12
2019; 71
2015; 17
2017; 3
2013; 65
2017; 69
2009; 60
2016; 388
2017; 390
2016; 75
2014; 370
2012; 367
2014; 41
2016; 18
2017; 177
2018; 20
2016; 34
2012; 71
2015; 25
2020; 2
2018; 5
2019; 21
2013; 72
2013; 159
2002; 46
2017; 76
2011; 63
2019
2007; 46
2012; 64
2016; 46
e_1_2_10_23_1
e_1_2_10_24_1
e_1_2_10_21_1
e_1_2_10_22_1
e_1_2_10_20_1
Kremer JM (e_1_2_10_19_1) 2016; 34
e_1_2_10_2_1
e_1_2_10_4_1
e_1_2_10_18_1
e_1_2_10_3_1
e_1_2_10_6_1
e_1_2_10_16_1
e_1_2_10_5_1
e_1_2_10_17_1
e_1_2_10_8_1
e_1_2_10_14_1
e_1_2_10_7_1
e_1_2_10_15_1
e_1_2_10_12_1
e_1_2_10_35_1
e_1_2_10_9_1
e_1_2_10_13_1
e_1_2_10_34_1
e_1_2_10_10_1
e_1_2_10_33_1
e_1_2_10_11_1
e_1_2_10_32_1
e_1_2_10_31_1
e_1_2_10_30_1
e_1_2_10_29_1
e_1_2_10_27_1
e_1_2_10_28_1
e_1_2_10_25_1
e_1_2_10_26_1
References_xml – volume: 18
  start-page: 34
  year: 2016
  article-title: Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open‐label, long‐term extension study
  publication-title: Arthritis Res Ther
– volume: 5
  start-page: 283
  year: 2018
  end-page: 91
  article-title: Worldwide, 3‐year, post‐marketing surveillance experience with tofacitinib in rheumatoid arthritis
  publication-title: Rheumatol Ther
– volume: 25
  start-page: 514
  year: 2015
  end-page: 21
  article-title: Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12‐week, randomized, phase 2 study
  publication-title: Mod Rheumatol
– volume: 367
  start-page: 508
  year: 2012
  end-page: 19
  article-title: Tofacitinib or adalimumab versus placebo in rheumatoid arthritis
  publication-title: N Engl J Med
– volume: 71
  start-page: 1524
  year: 2012
  end-page: 9
  article-title: Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta‐analysis of observational studies
  publication-title: Ann Rheum Dis
– volume: 71
  start-page: 878
  year: 2019
  end-page: 91
  article-title: Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: clinical efficacy, radiographic, and safety outcomes from a twenty‐four‐month, phase III study
  publication-title: Arthritis Rheumatol
– volume: 41
  start-page: 837
  year: 2014
  end-page: 52
  article-title: Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open‐label, longterm extension studies
  publication-title: J Rheumatol
– volume: 69
  start-page: 1969
  year: 2017
  end-page: 77
  article-title: The safety and immunogenicity of live zoster vaccination in patients with rheumatoid arthritis before starting tofacitinib: a randomized Phase II trial
  publication-title: Arthritis Rheumatol
– volume: 3
  year: 2017
  article-title: Infection rates in patients from five rheumatoid arthritis (RA) registries: contextualising an RA clinical trial programme
  publication-title: RMD Open
– volume: 388
  start-page: 2023
  year: 2016
  end-page: 38
  article-title: Rheumatoid arthritis
  publication-title: Lancet
– volume: 63
  start-page: 1150
  year: 2011
  end-page: 8
  article-title: Tofacitinib Study Investigators. Phase II study of tofacitinib (CP‐690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate
  publication-title: Arthritis Care Res (Hoboken)
– volume: 34
  start-page: S96
  year: 2016
  end-page: 9
  article-title: The Corrona US registry of rheumatic and autoimmune diseases
  publication-title: Clin Exp Rheumatol
– volume: 60
  start-page: 1895
  year: 2009
  end-page: 905
  article-title: The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double‐blind, placebo‐controlled phase IIa trial of three dosage levels of CP‐690,550 versus placebo
  publication-title: Arthritis Rheum
– volume: 21
  start-page: 89
  year: 2019
  article-title: Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open‐label, long‐term extension study
  publication-title: Arthritis Res Ther
– volume: 12
  start-page: R5
  year: 2010
  article-title: Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT
  publication-title: Arthritis Res Ther
– volume: 64
  start-page: 617
  year: 2012
  end-page: 29
  article-title: Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs
  publication-title: Arthritis Rheum
– volume: 64
  start-page: 970
  year: 2012
  end-page: 81
  article-title: A phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone
  publication-title: Arthritis Rheum
– volume: 390
  start-page: 457
  year: 2017
  end-page: 68
  article-title: Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double‐blind, head‐to‐head, randomised controlled trial
  publication-title: Lancet
– volume: 75
  start-page: 1843
  year: 2016
  end-page: 7
  article-title: Real‐world comparative risks of herpes virus infections in tofacitinib and biologic‐treated patients with rheumatoid arthritis
  publication-title: Ann Rheum Dis
– volume: 370
  start-page: 2377
  year: 2014
  end-page: 86
  article-title: Tofacitinib versus methotrexate in rheumatoid arthritis
  publication-title: N Engl J Med
– volume: 76
  start-page: 1253
  year: 2017
  end-page: 62
  article-title: Long‐term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials
  publication-title: Ann Rheum Dis
– volume: 65
  start-page: 559
  year: 2013
  end-page: 70
  article-title: Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve‐month data from a twenty‐four‐month phase III randomized radiographic study
  publication-title: Arthritis Rheum
– volume: 367
  start-page: 495
  year: 2012
  end-page: 507
  article-title: Placebo‐controlled trial of tofacitinib monotherapy in rheumatoid arthritis
  publication-title: N Engl J Med
– volume: 46
  start-page: 2287
  year: 2002
  end-page: 93
  article-title: Frequency of infection in patients with rheumatoid arthritis compared with controls: a population‐based study
  publication-title: Arthritis Rheum
– volume: 177
  start-page: 1605
  year: 2017
  end-page: 12
  article-title: Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: a nationwide cohort study from Sweden
  publication-title: JAMA Intern Med
– volume: 2
  start-page: E84
  year: 2020
  end-page: E98
  article-title: Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study
  publication-title: Lancet Rheumatol
– volume: 72
  start-page: 517
  year: 2013
  end-page: 24
  article-title: Adalimumab: long‐term safety in 23458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease
  publication-title: Ann Rheum Dis
– volume: 159
  start-page: 253
  year: 2013
  end-page: 61
  article-title: Tofacitinib in combination with nonbiologic disease‐modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial
  publication-title: Ann Intern Med
– volume: 46
  start-page: 350
  year: 2007
  end-page: 7
  article-title: Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis
  publication-title: Rheumatology (Oxford)
– volume: 46
  start-page: 261
  year: 2016
  end-page: 71
  article-title: Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor
  publication-title: Semin Arthritis Rheum
– year: 2019
– volume: 17
  start-page: 212
  year: 2015
  article-title: Incidence of malignancy in adult patients with rheumatoid arthritis: a meta‐analysis
  publication-title: Arthritis Res Ther
– volume: 64
  start-page: 2847
  year: 2012
  end-page: 55
  article-title: Development and validation of a risk score for serious infections in patients with rheumatoid arthritis
  publication-title: Arthritis Rheum
– volume: 20
  start-page: 2
  year: 2018
  article-title: One‐year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real‐world setting: data from a national U.S. rheumatoid arthritis registry
  publication-title: Arthritis Res Ther
– ident: e_1_2_10_15_1
  doi: 10.1016/S0140-6736(17)31618-5
– ident: e_1_2_10_16_1
  doi: 10.3899/jrheum.130683
– ident: e_1_2_10_22_1
  doi: 10.1093/rheumatology/kel253
– ident: e_1_2_10_34_1
  doi: 10.1002/art.40187
– ident: e_1_2_10_27_1
  doi: 10.1002/art.34530
– ident: e_1_2_10_12_1
  doi: 10.1002/art.37816
– ident: e_1_2_10_35_1
  doi: 10.1186/s13075-015-0728-9
– ident: e_1_2_10_11_1
  doi: 10.1056/NEJMoa1310476
– ident: e_1_2_10_33_1
  doi: 10.1136/rmdopen-2017-000498
– ident: e_1_2_10_3_1
  doi: 10.1002/art.33383
– ident: e_1_2_10_17_1
  doi: 10.1186/s13075-016-0932-2
– ident: e_1_2_10_9_1
  doi: 10.1056/NEJMoa1109071
– ident: e_1_2_10_8_1
  doi: 10.1136/annrheumdis-2011-201244
– ident: e_1_2_10_21_1
  doi: 10.1001/jamainternmed.2017.4332
– ident: e_1_2_10_2_1
  doi: 10.1016/S0140-6736(16)30173-8
– ident: e_1_2_10_6_1
  doi: 10.1002/acr.20494
– ident: e_1_2_10_20_1
  doi: 10.1186/ar2904
– ident: e_1_2_10_4_1
  doi: 10.1002/art.24567
– ident: e_1_2_10_13_1
  doi: 10.1056/NEJMoa1112072
– ident: e_1_2_10_7_1
  doi: 10.3109/14397595.2014.995875
– ident: e_1_2_10_14_1
  doi: 10.1002/art.40803
– volume: 34
  start-page: S96
  year: 2016
  ident: e_1_2_10_19_1
  article-title: The Corrona US registry of rheumatic and autoimmune diseases
  publication-title: Clin Exp Rheumatol
– ident: e_1_2_10_5_1
  doi: 10.1002/art.33419
– ident: e_1_2_10_30_1
  doi: 10.1186/s13075-017-1496-5
– ident: e_1_2_10_32_1
  doi: 10.1136/annrheumdis-2016-209131
– ident: e_1_2_10_26_1
  doi: 10.1002/art.10524
– ident: e_1_2_10_10_1
  doi: 10.7326/0003-4819-159-4-201308200-00006
– ident: e_1_2_10_24_1
  doi: 10.1016/j.semarthrit.2016.05.014
– ident: e_1_2_10_28_1
  doi: 10.1136/annrheumdis-2016-210457
– ident: e_1_2_10_25_1
– ident: e_1_2_10_31_1
  doi: 10.1007/s40744-018-0097-3
– ident: e_1_2_10_18_1
  doi: 10.1186/s13075-019-1866-2
– ident: e_1_2_10_29_1
  doi: 10.1016/S2665-9913(19)30137-7
– ident: e_1_2_10_23_1
  doi: 10.1136/annrheumdis-2011-200726
SSID ssj0002150764
Score 2.4794629
Snippet Objective Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We compared 5‐year adverse event (AE) incidence rates...
Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We compared 5-year adverse event (AE) incidence rates (IRs)...
ObjectiveTofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We compared 5‐year adverse event (AE) incidence rates...
ObjectiveTofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We compared 5-year adverse event (AE) incidence rates...
Objective Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We compared 5‐year adverse event (AE) incidence rates...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
wiley
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 173
SubjectTerms Clinical trials
Comparative analysis
Data collection
Drug dosages
FDA approval
Original
Patients
Prescription drugs
Rheumatoid arthritis
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELZQD4gLovxuKcgILiBF3diOk3DbbqkqpOWwtFI5RbZjdyNVCdpNDr31ESrxMjxPn4QZOw27YgUXTonsieV4xp7P8vgbQt5Ziym1WRylQvBIZLGMwAuKSOcxU3pcxqnBjeLsizw5E5_Pk_O1VF8YExbogcPAHQDAdyaWOoM9nCgVnlPxUug0N4D9ufT3yMHnrW2mcA1miHOkGPhI2YEyS4b3ZTjb8ECeqH8buvwzSHIdvHrvc_yIPOxhI52E7u6Se7Z-TO7P-oPxJ-QnJt31_OBgOXT6m9KbflXOtlcU4wWvaOPoaeOUqdqqrjRVdUlDMkpUFT0KhzW31zezpqz8BSg6qdtqubCdZ3alR8vuYvWRJiDyDaYIndtVd9muKF5SoYoGAEsDgL29_nEIrZV0Hj5vqhL7v_AsSvDlhc8z95ScHX86nZ5EfVKGyEiAC5FSUua5EPBIHeOK50q7rMzGZWI0t8jnp1IHPlCqBEuVdVqPOSyMYzO2QvJnZKduavuCUAtowjlYcQFEgC81mZLMJLGW1rrU5HxE3t8pqjA9YzkmzrgsAtcyK1CphVfqiLwdZL8Hno6tUoeo70ECubV9AVhc0Vtc8S-LG5H9O2sp-gm_KgBJYir5OMu3V2cIJTOZQPWboRpmMh7PqNo2HcjAWpoAAMUffx5sb-go50mK7G8jkm5Y5cafbNbU1cKzhaewoc0yaPODt9-_jE4xmc6Zf9v7H-P0kjxgGADkA_b2yU677OwrQHCtfu0n6y9yCEY4
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dbtMwFLZgSIgbxP86BjKCG5CiNbZjJ9ygrmOakMpF2aRyFdmO3UaaktGmF7vbO_AqPBFPwjlOGqiodtUqdqI458effY6_Q8g757CkNosjJQSPRBrLCGZBEZksZtoMi1hZXChOvsqzC_Fllsy6DbdVl1a58YnBURe1xT3yI4wAxniMMvt09SPCqlEYXe1KaNwl95C6DFO61Ez1eywM0Y4UPSspO9J2yfDUDGdb81Cg69-FMf9PlfwXwoY56PQRediBRzpqpf2Y3HHVE3J_0oXHn5JfWHo3sISD_tDxX2Jv-k1711xTzBq8prWn57XXtmzKqjRUVwVtS1KiwOhJG7KJJnVRhkNQdFQ15XLh1oHdlZ4s1_PVR5pE38FI6NSt1pfNiuIxFappC2FpC2F_3_w8hicVdNreXJcFvvsi8CjBnfNQae4ZuTj9fD4-i7qyDJGVABgiraXMMiHgR3nGNc-08WmRDovEGu6Q0U8rD7Og1Ale1c4bM-TgGod26ITkz8leVVdun1AHeMJ78LkAI2A2tamWzCaxkc55ZTM-IO83Qsptx1mOpTMu85ZtmeUo0DwIdEDe9n2vWqaOnb2OUdZ9D2TXDhfq5TzvjDWHRaW3sTSpEkwUGmOjvBBGZRbWm1yqATncaEremfwqByyJxeTjNNvd3OvvgLzpm8GWMUCjK1evoQ940wQgKA78Rat3_YtynijkfxsQtaWRWyPZbqnKReALV7CkTVN45oegu7d8nXw0nrLw7-D2MbwkDxgm94RkvEOy1yzX7hWgs8a8Dib4B_IaO4c
  priority: 102
  providerName: ProQuest
Title Postapproval Comparative Safety Study of Tofacitinib and Biological Disease‐Modifying Antirheumatic Drugs: 5‐Year Results from a United States–Based Rheumatoid Arthritis Registry
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Facr2.11232
https://www.ncbi.nlm.nih.gov/pubmed/33570260
https://www.proquest.com/docview/2501714189
https://www.proquest.com/docview/2806128659
https://www.proquest.com/docview/2488556093
https://pubmed.ncbi.nlm.nih.gov/PMC7966883
https://doaj.org/article/619fc16b87424da49083d4b79c261367
Volume 3
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3datswFBalhbGbsf-l64LGdrOBaSzJlj12k6QtZZBSsmZkuzGSLCeGYo_EuehdH2Gwl9nz9El2juw4CwuD3djGOjK2z48-_X2HkLfWYkpt5ntSCO6JyA89aAWFp2OfKd1LfWmwozi6CM8n4tM0mO6Rj-u9MDU_RDvghp7h4jU6uNLL4w1pqDILhhtgOATgA9xbi8z5TFy2IywMsY7jj0Kz9AIpgpaflB1vqm-1SI64fxfa_HvR5J9g1rVGZw_JgwZG0n6t90dkzxaPyb1RM1H-hPzCJLyOLxwsiQ43FN_0s8psdUNx_eANLTN6VWbK5FVe5JqqIqV1ckpUHT2pJ2_ubn-MyjR3G6Jov6jyxdyuHNMrPVmsZssPNACRr-AydGyXq-tqSXHTClW0BrS0BrR3tz8H8LSUjuvqZZ7i-88dqxLUnLm8c0_J5Oz0anjuNUkaPBMCfPCUCsM4FgJOMmNc8VjpLEqjXhoYzS3y-ymZQZsYqgDvKptp3eMQKHumZ0XIn5H9oizsC0ItoIssgwgMoALaVhOpkJnA16G1mTQx75B3a0UlpmEwx0Qa10nNvcwSVGrilNohb1rZ7zVvx06pAeq7lUCubXejXMySxnUT6GJmxg91JAUTqcKZUp4KLWMDvU8eyg45WltL0gSAZQLIElPL-1G8uzhCaBmFARS_bovBs3G6RhW2XIEMxNYAACl--PPa9toX5TyQyAbXIXLLKre-ZLukyOeOPVxCBzeK4Jnvnf3-4-8k_eGYuavD_xF-Se4zXPjjFuodkf1qsbKvALlVuuscFI5yKrvkoP9l8m0C58HpxeW460ZDfgPUL0aQ
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3dbtMwFLZGJwE3iH8KA4yAC5CiNbbjJEgI9WdTx9YKlU3aroLjOG2kKRn9Eeod78B7cMUT8SSc46SBimp3u2oVO1acc3z8nRyf7xDyyhgsqc1cxxeCOyJwpQO7oHDi0GUqbiWur9FRHAxl_0R8PPVOt8jPVS4MHqtc2URrqJNC4zfyXYwAuphGGX64-Opg1SiMrq5KaJRqcWiW38Blm70_6IF8XzO2v3fc7TtVVQFHS9jvHKWkDEMh4MdPGVc8VHEaJEEr8XTMDRLSKT8FIy6Vh1eVSeO4xWFlt3TLCMlh3GtkW3BwZRpku7M3_DSqv-owxFdS1DyobFfpKcM8Hc7Wdj5bIGATqv3_cOa_oNnuevu3ya0KrtJ2qV93yJbJ75Lrgyogf4_8wmK_lpccNJZ2_1KJ088qNfMlxXOKS1qk9LhIlc7mWZ7FVOUJLYtgoorQXhkkcgZFktm0K9rO59l0YhaWT5b2povx7B31nDN4_3RkZovz-YxiYgxVtATNtATNv7__6MBICR2VNxdZgs8-scxNcOfY1ra7T06uRGQPSCMvcvOIUAMIJk3BygNwgf1bB0oy7bmxNCb1dcib5M1KSJGuWNKxWMd5VPI7swgFGlmBNsnLuu9FyQ2ysVcHZV33QD5ve6GYjqPKPETgxqbalXHgCyYShdFYnojYDzV4uFz6TbKz0pSoMjKzCNArlq93g3Bzc71imuRF3QzWA0NCKjfFAvqA_fYA9OLEH5Z6Vz8o556PjHNN4q9p5NpM1lvybGIZyn1wooMAxnxrdfeStxO1uyNm_z2-fA7PyY3-8eAoOjoYHj4hNxkeLbJHAXdIYz5dmKeADefxs2pBUvLlqm3AH_O8eWA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3dbtMwFLbGkCZuEP8UBhgBFyBFbezETpAQ6lqqjdEJjU0qV8Fx7DbSlIz-CPWOd-BVuOJxeBLOcdJARbW7XbWKHSvO-fHnnOPvEPLcGCypzXxPBgH3gsgXHqyCgZfGPlNpJ_Olxo3i8EjsnwbvR-Foi_xanYXBtMqVT3SOOis1fiNvYwTQx2OUcdvWaREf-4O35189rCCFkdZVOY1KRQ7N8hts32ZvDvog6xeMDd6d9Pa9usKApwWsfZ5SQsRxEMCPtIwrHqvURlnUyUKdcoPkdEpacOhChXhVGZumHQ5W3tEdEwgO414hVyUPfbQxOZLN9x2GSEsEDSMqays9ZXhih7O1NdCVCtiEb_9P0_wXPrv1b3CDXK-BK-1WmnaTbJniFtkZ1qH52-Qnlv11DOWgu7T3l1ScflLWzJcUMxaXtLT0pLRK5_O8yFOqioxW5TBRWWi_Chd5wzLL3QEs2i3m-XRiFo5Zlvani_HsNQ29z_D26bGZLc7mM4pHZKiiFXymFXz-_f3HHoyU0ePq5jLP8NknjsMJ7hy7Knd3yOmlCOwu2S7Kwtwn1ACWsRb8PUAYWMl1pATToZ8KY6zUMW-RlyshJbrmS8eyHWdJxfTMEhRo4gTaIs-avucVS8jGXnso66YHMnu7C-V0nNSOIoENrdW-SCMZsCBTGJflWZDKWMNelwvZIrsrTUlqdzNLAMdiIXs_ijc3N7bTIk-bZvAjGBxShSkX0Ac8eQjwFyd-r9K75kE5DyVyz7WIXNPItZmstxT5xHGVS9hORxGM-crp7gVvJ-n2jpn79-DiOTwhO2D5yYeDo8OH5BrDHCOXE7hLtufThXkEIHGePnbWSMmXyzb_PxjlfDA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Postapproval+Comparative+Safety+Study+of+Tofacitinib+and+Biological+Disease%E2%80%90Modifying+Antirheumatic+Drugs%3A+5%E2%80%90Year+Results+from+a+United+States%E2%80%93Based+Rheumatoid+Arthritis+Registry&rft.jtitle=ACR+open+rheumatology&rft.au=Kremer%2C+Joel+M.&rft.au=Bingham%2C+Clifton+O.&rft.au=Cappelli%2C+Laura+C.&rft.au=Greenberg%2C+Jeffrey+D.&rft.date=2021-03-01&rft.issn=2578-5745&rft.eissn=2578-5745&rft.volume=3&rft.issue=3&rft.spage=173&rft.epage=184&rft_id=info:doi/10.1002%2Facr2.11232&rft.externalDBID=10.1002%252Facr2.11232&rft.externalDocID=ACR211232
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2578-5745&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2578-5745&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2578-5745&client=summon